Key players in pancreatic cancer-stroma interaction

Cancer-associated fibroblasts, endothelial and inflammatory cells

Nielsen, Michael Friberg Bruun; Mortensen, Michael Bau; Detlefsen, Sönke

Published in:
World Journal of Gastroenterology

DOI:
10.3748/wjg.v22.i9.2678

Publication date:
2016

Document version
Publisher's PDF, also known as Version of record

Document license
CC BY-NC

Citation for published version (APA):
Nielsen, M. F. B., Mortensen, M. B., & Detlefsen, S. (2016). Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells. World Journal of Gastroenterology, 22(9), 2678-2700. DOI: 10.3748/wjg.v22.i9.2678

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Download date: 03. Nov. 2018
Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells

Michael Friberg Bruun Nielsen, Michael Bau Mortensen, Sönke Detlefsen

Abstract
Pancreatic cancer (PC) is the most aggressive type of common cancers, and in 2014, nearly 40000 patients died from the disease in the United States. Pancreatic ductal adenocarcinoma, which accounts for the majority of PC cases, is characterized by an intense stromal desmoplastic reaction surrounding the cancer cells. Cancer-associated fibroblasts (CAFs) are the main effector cells in the desmoplastic reaction, and pancreatic stellate cells are the most important source of CAFs. However, other important components of the PC stroma are inflammatory cells and endothelial cells. The aim of this review is to describe the complex interplay between PC cells and the cellular and non-cellular components of the tumour stroma. Published data have indicated that the desmoplastic stroma protects PC cells against chemotherapy and radiation therapy and that it might promote the proliferation and migration of PC cells. However, in animal studies, experimental depletion of the desmoplasic stroma and CAFs has led to more aggressive cancers. Hence, the precise role of the tumour stroma in PC remains to be elucidated. However, it is likely that a context-dependent therapeutic modification, rather than pure depletion, of the PC stroma holds potential for the development of new treatment strategies for PC patients.

Key words: Pancreatic cancer; Desmoplastic stroma; Cancer-associated fibroblast; Inflammatory cells; Pancreatic stellate cell
response to chemotherapeutics, which are often directed against the PC cells. One of the histological hallmarks of PC is the extensive desmoplastic stromal reaction that surrounds the PC cells. The PC stroma is not simply a bystander of the neoplastic process but plays an active part in disease progression and metastasis. The PC cells, cancer-associated fibroblasts, inflammatory cells, endothelial cells, and the extracellular matrix engage in a complex interplay, the modulation of which could hold potential for the future development of new PC therapies.

Nielsen MFB, Mortensen MB, Detlefsen S. Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells. World J Gastroenterol 2016; 22(9): 2678-2700 Available from: URL: http://www.wjgnet.com/1007-9327/full/v22/i9/2678.htm DOI: http://dx.doi.org/10.3748/wjg.v22.i9.2678

INTRODUCTION

In 2014, pancreatic cancer (PC) was the fourth leading cause of cancer-associated deaths in the United States, with 46420 estimated new cases and 39590 estimated deaths[1]. The 5-year PC survival rate is approximately 5%, and surgical resection offers the only option for long-term survival[2]. However, even for patients who undergo surgery for localized disease, the 5-year survival rate is only approximately 20%[2].

Pancreatic ductal adenocarcinoma (PDAC) accounts for approximately 85% of all PCs, and most of the published data have indicated that PDAC arises from ductal epithelial cells[3,4]. However, an alternative hypothesis, called acinar-ductal metaplasia (ADM), suggests that PDAC arises from the centro-acinar acinar compartment (CAAC)[4]. According to a well-established progression model for the development of PDAC, the normal duct epithelium progresses to invasive adenocarcinoma through histologically well-defined stages of duct lesions, the so-called pancreatic intraepithelial neoplasias (PanINs)[5,6]. However, not all PanINs will progress to invasive cancer. The PanIN subsets are histologically distinctive and genetic alterations characteristic of invasive adenocarcinomas can be identified in early ductal lesions[5]. Molecular abnormalities, which include the overexpression of oncogenes (K-ras and HER2/neu) and the deletion of tumour-suppressor genes (p16, p53, DPC4, and BRCA2), accumulate during progression through the different PanIN stages[5,7]. In support of the credibility of this progression model, approximately two-thirds of somatic mutations have been found to be shared between PanINs and associated invasive carcinomas[8]. Animal models using rats and transgenic mice, however, found that so-called tubular complexes, which are thought to originate via ADM, might be important precursor lesions in PDAC[9-11]. In subsequent studies using genetically engineered mouse models (GEMMs) and human tissue, it was hypothesized that ADM might progress and contribute to the development of PanINs[12,13]. In support of the ADM hypothesis, ADM-associated atypical flat lesions were found to be the most likely PDAC precursor in KrasG12D/+; Ptf1a-CreERT2 GEMMs and in patients with family histories of PDAC, but not in sporadic PDAC[4]. In sporadic PDAC, however, tubular complexes and mucinous tubular complexes were frequently found.

Studies using PC animal models, especially GEMMs, have contributed to the understanding of PDAC progression[14,15]. GEMMs are considered superior to xenograft models, in which PC tumours are formed when human PC cells are introduced into immunocompromised mice. In GEMMs of PC, endogenous expression of K-ras is switched on in the progenitor cells of the mouse pancreas[10]. Such molecular modifications result in progression to invasive PC through distinct stages of ductal lesions that mimic human PanINs. Human 3-dimensional (3D) organotypic models have contributed to the characterization of tumour-stroma crosstalk in PC[17,18]. The organotypic model is a simplified representation of the complex in vivo 3D microenvironment. Organotypic models are relatively easy manipulated, and they constitute a useful tool for the systematic examination of antitumor therapies.

The most common symptoms in patients with PC are asthenia, anorexia, weight loss, icterus, and abdominal pain[10]. The majority of PC patients are diagnosed in the late stage of disease, when surgical resection is no longer an option. Currently, effective screening tools to detect premalignant or early stages of the disease are not available. Both inherent and environmental factors are key contributors to the development of PC[20]. Cigarette smoking is the most important predisposing factor. Up to 20%-25% of all PC cases can be attributed to smoking, and current smokers have a 2.2-fold higher risk of developing PC than people who have never smoked[21,22]. Other important risk factors include type 2 diabetes, chronic pancreatitis, and heavy alcohol consumption[23-27]. According to a meta-analysis of seven case-control and two cohort studies including 6568 patients, individuals with family histories of PC had a nearly 2-fold increased risk of developing PC[28]. Approximately 10% of all PC cases have a familial background, and BRCA2, PALP2, and p16 germine mutations have been associated with familial pancreatic cancer (FPC)[29]. FPC is defined as PC occurring in a patient with two or more first-degree relatives with PC[11,30]. FPC is inherited as an autosomal dominant trait with high penetrance in family members[31]. The risk of developing PC is very high in cases with hereditary pancreatitis, which is most often caused by mutations in the cationic trypsinogen gene (PRSS1)[32].

PDAC is distinguished from many other cancer types by the excessive amount of scar tissue ("desmoplasia") that surrounds the malignant cells and occupies up to...
80% of the entire cancer nodule. The desmoplastic stroma consists predominantly of cancer-associated fibroblasts (CAFs), inflammatory cells, small blood vessels, and extracellular matrix (ECM). Resistance to therapy is the most important clinical challenge in PC. The increased use of combination chemotherapy could benefit selected patients in both a palliative and neo-adjuvant setting, but this treatment strategy is non-specific and has no significant impact on long-term outcome. Numerous studies have now documented tumour-promoting functions of the key components of the tumour stroma, including CAFs, ECM, endothelial cells, and inflammatory cells. However, mouse studies focused on stromal depletion have illustrated a tumour-suppressing, rather than a tumour-promoting, role of the stromal compartment. Hence, the precise role of the tumour stroma is currently controversial, and the aim of this review is to assess the context-dependent role of the various stromal components in the development of PC, as well as their potential for the future development of new treatment strategies.

CAFS AND THE INTERACTION BETWEEN CAFS AND PC CELLS

CAFs, originally known as carcinoma-associated fibroblasts, play a significant role in tumour growth and progression. These cells display a myofibroblast-like phenotype, characterized by a spindle shape and the expression of α-smooth muscle actin (α-SMA). Functionally, CAFs are characterized by their production of a wide variety of ECM molecules and cytokines.

Origin of cancer-associated fibroblasts

CAFs can originate from different cellular sources, including pancreatic stellate cells (PSCs), which are considered to be the most important source by far, and probably resident fibroblasts and bone marrow-derived cells (BMDCs) (Figure 2). Epithelial cells, through epithelial-mesenchymal transition, have also been proposed as a cellular source of CAFs, but this hypothesis is still under debate.

PSCs: PSCs are the most important cellular source of CAFs in PC. Additionally, PSCs are the main effector cells in the fibrotic process of chronic pancreatitis. PSCs have much in common with hepatic stellate cells (HSCs) because they both store vitamin A and are both characterized by their stellate morphology. PSCs came into focus when they were isolated and cultured by two independent research groups in 1998. However, retrospectively, it was probably the same vitamin A-storing cell described by Watari in mice and by Ikejiri...
Additionally, human aPSCs were deactivated when cultured on Matrigel and treated with N-acetylcysteine (NAC) [62]. NAC induced similar cell cycle arrest in activated HSCs through the mitogen-activated protein kinase (MAPK) pathway [63]. Activated PSCs lose their vitamin A lipid vacuoles, develop a spindle-shaped morphology, and begin to express α-SMA [46,47]. They differ from their quiescent counterparts in that they proliferate and develop migratory and phagocytic properties [50,64]. The secreted proteomes of cultured qPSCs and aPSCs have been compared, utilizing an immortalized cell line derived from human PSCs [65]. Proteomic profiling identified 641 unique proteins secreted by aPSC, compared to only 46 unique proteins identified in qPSCs. These proteins were associated with proliferation, inflammation, ECM remodelling, cell motility, and invasion, supporting an active role for aPSCs in PC progression [65].

Bone marrow-derived cells: CAFs can arise from stem cells originating from the bone marrow [66-69]. Bone marrow-derived cells (BMDCs) were recruited to the pancreatic stroma in a rat model of acute pancreatitis induced by a choline-deficient/ethionine-supplemented diet [70]. Tagged BMDCs from female mice were transplanted into male rats and contributed to the aPSC pool, as indicated by their expression of desmin and α-SMA. In an experimental chronic pancreatitis mouse model, BMDCs were tracked with green fluorescent protein on the Y-chromosome in sex-mismatched transplanted mice [66]. Desmin-positive

In humans [48,49]. In the normal pancreas, quiescent PSCs (qPSCs) are located in the periacinar space, and in the rat pancreas, they constitute approximately 4% of all parenchymal cells [46,47]. qPSCs function as a storage site for vitamin A and might be involved in ECM turnover because they have the capacity to produce matrix metalloproteinases (MMPs) [50]. Numerous biomarkers for qPSCs have been reported [39], including desmin [46,47], nestin [51], vimentin [47], synemin [52], and glial fibrillary acidic protein (GFAP) [46], but some of these markers have been identified in rats only, and most of them are not entirely specific for qPSCs. Hence, entirely specific immunohistochemical biomarkers for human qPSCs applicable in routine diagnostics have yet to be identified. During tissue injury or carcinogenesis, qPSCs become activated, attaining a state called activated PSCs (aPSCs), and they develop a myofibroblast-like phenotype [39] (Figure 3). There are several factors that activate qPSCs, such as platelet-derived growth factor (PDGF), transforming growth factor beta (TGFβ), tumour necrosis factor alpha (TNFα), and interleukins 1, 6, and 10 (IL-1, IL6 and IL10) [55]. PSCs express receptors for most of these cytokines in chronic pancreatitis, as well as in PDAC [44,45,56,57]. Activated PSCs, in turn, produce PDGF and TGFβ, which contribute to autocrine signalling [58,59]. Cultured rat qPSCs are activated by alcohol derivatives and oxidative stress, which could explain the fibrotic reaction in alcoholic chronic pancreatitis [60]. This activation is a reversible process because incubation of PSCs with trans-retinoic acid induced quiescence in aPSCs in vitro [61]. Additionally, human aPSCs were deactivated when cultured on Matrigel and treated with N-acetylcysteine (NAC) [62]. NAC induced similar cell cycle arrest in activated HSCs through the mitogen-activated protein kinase (MAPK) kinase pathway [63].

Activated PSCs lose their vitamin A lipid vacuoles, develop a spindle-shaped morphology, and begin to express α-SMA [46,47]. They differ from their quiescent counterparts in that they proliferate and develop migratory and phagocytic properties [50,64]. The secreted proteomes of cultured qPSCs and aPSCs have been compared, utilizing an immortalized cell line derived from human PSCs [65]. Proteomic profiling identified 641 unique proteins secreted by aPSC, compared to only 46 unique proteins identified in qPSCs. These proteins were associated with proliferation, inflammation, ECM remodelling, cell motility, and invasion, supporting an active role for aPSCs in PC progression [65].
BMDCs engrafted to the pancreas and contributed to approximately 5% of all PSCs. A fraction of the bone marrow-derived cells expressed α-SMA, indicating that BMDCs had been activated and had contributed to tissue repair. In another study, BMDCs were transplanted from male β-actin-EGFP mice into female C57/BL6 mice, which were divided into two groups. One group had caerulein-induced chronic pancreatitis and the other had dimethylbenzanthracene (DMBA)-induced PC. The engrafted BMDCs contributed to the population of aPSCs in fibrotic areas in both groups. Similar observations had already been made in rats in a 2009 study. Chronic pancreatitis is a risk factor for the development of PC, and based on the above studies, it is tempting to speculate that BMDCs might contribute to the CAF population in human PC.

It has been documented that BMDCs with a fibrocyte precursor phenotype (CD45+, collagen 1+) circulate in the peripheral blood before engrafting to the fibrotic pancreas. In the pancreas, as well as other organs, mature fibrocytes transform into myofibroblasts and participate in fibrogenesis by producing ECM and MMPs, and based on the above studies, they seem to be the most useful marker for fibroblasts in vivo. In the mouse pancreas, FSP-1 expression has been identified in interlobular fibroblasts, as well as in in dendritic cells and aPSCs. In PDAC, FSP-1 has been documented in both human and mouse CAFs as well as in human PC cells. The above studies demonstrate that FSP-1 is not a totally specific marker for resident pancreatic fibroblasts. High FSP-1 expression in human PDAC has been associated with increased invasion and shorter survival.

Upon tissue damage, cell necrosis/apoptosis leads to the release of inflammatory cytokines (e.g., TGFβ1 and PDGF) and chemokines from local inflammatory cells, endothelial cells, or mesenchymal cells. Subsequently, resident fibroblasts are activated, and they proliferate and differentiate into myofibroblasts, thereby contributing to the CAF pool. However, this process has not yet been documented in human PDAC, in which qPSCs seem to be by far the most important source of CAFs.

**Resident fibroblasts:** Resident (local) fibroblasts are an important CAF source in many types of cancers. Fibroblasts are abundant in connective tissue, producing ECM and contributing to tissue homeostasis. They are of mesodermal origin and characterized by their spindle shape and extended cell processes. In the desmoplastic reaction, and they synthesize extracellular matrix (ECM) proteins. Further, they produce the growth factors and cytokines that promote cancer cell proliferation and migration.

**Figure 3 Activation of quiescent pancreatic stellate cells in pancreatic cancer.** In the normal pancreas, pancreatic stellate cells are in the quiescent state (qPSCs) and located in the periacinar space. They have a stellate morphology and contain vitamin A lipid vacuoles. During carcinogenesis, they become activated (aPSCs). aPSCs are the most important cellular source of cancer-associated fibroblasts (CAFs) in PC. CAFs, characterized by a spindle-shaped morphology, are the main effector cells in the desmoplastic reaction, and they synthesize extracellular matrix (ECM) proteins. Further, they produce the growth factors and cytokines that promote cancer cell proliferation and migration.
cultured PDAC cells induced the proliferation and production of ECM proteins in PSCs\(^{[89]}\). Conversely, CAF culture media induced the proliferation and migration of PDAC cells, and the growth rate of PDAC cells was markedly increased when PSCs were co-injected into nude mice\(^{[89-91]}\).

To mimic the in vivo crosstalk between PC cells and stromal cells, 3D cell cultures of human PC cells and immortalized PSCs were cultured on Matrigel and collagen, simulating the in vivo PDAC microenvironment\(^{[92]}\). Under these conditions, PSCs modulated the expression of adhesion molecules on the cancer cells, increasing their invasiveness, in association with the downregulation of E-cadherin and the upregulation of β-catenin\(^{[93]}\). These findings suggest that PSCs could play an important role in PC metastasis. Another study co-cultured PSCs with PDAC cells using conventional cell cultures\(^{[93]}\). The epithelial markers E-cadherin, cytokeratin 19, and β-catenin were downregulated in PDAC; the mesenchymal markers vimentin and snail were upregulated; and cancer cell migration was increased\(^{[93]}\). In an orthotopic xenograft mouse model, in which male human PSCs were co-injected with female PDAC cells into the pancreases of female mice, PSCs followed the PC cells to the metastatic sites, suggesting that PSCs could play a role in the settlement of metastatic PDAC cells\(^{[94]}\).

**CAFs protect cancer cells against chemoradiation therapy**

In addition to their role as promoters of PC cell proliferation and migration, CAFs have also been shown to protect PC cells from chemotherapy and radiation therapy (CRT). Hwang et al\(^{[93]}\) isolated human PSCs from resected PC samples and developed an immortalized cell line. When the in vitro effects of PSC-conditioned media on PC cell survival were assessed in the presence of gemcitabine (100 μmol/L) or radiation therapy (100-Gy), components in the PSC media protected the PC cells against apoptosis\(^{[90]}\).

Using monocultures or direct co-culture of PC cells with PSCs, PC cell survival during radiation was increased in the presence of PSCs\(^{[91,95]}\). This radioprotective effect of PSCs was significantly reduced using antibodies blocking β1-integrin signalling\(^{[91]}\). However, in this study, it was not confirmed that PSC-conditioned media displayed radioprotective properties, and it was suggested that direct contact between PSCs and the PDAC cells was necessary\(^{[91]}\). The ability of PSCs to radioprotect PC cells in vivo was demonstrated in xenograft models in which nude mice received subcutaneous injections of human PC cells alone or together with human PSCs\(^{[91,95]}\). Tumour growth was delayed as a response to radiation in both cases, but the response was less pronounced in tumours formed from both PC cells and PSCs than in tumours formed from PC cells alone\(^{[91,95]}\). Cultured human tumour-derived PSCs, obtained from fine-needle aspirates, had a more activated phenotype after exposure to CRT, compared to PSCs isolated prior to CRT\(^{[96]}\).

**Depletion and modulation of CAFs in the PDAC stroma**

Based upon the above observations, one would assume that a decrease in the CAF population would result in a concomitant decrease in PC cell proliferation/migration and an increased response to CRT. Data regarding the consequences of CAF depletion in the PDAC stroma have, however, been conflicting. The effect of gemcitabine was examined in KrasLSL.G12D/+; p53R172H/+; PdxCre+/+ (KPC) mice depleted of desmoplastic stroma and CAFs\(^{[97]}\). The KPC mouse is a frequently applied GEMM, expressing endogenous mutant Kras and p53 alleles in pancreatic cells and developing pancreatic tumours that morphologically closely resemble human PC\(^{[97]}\).

Like their human counterparts, the KPC mouse tumours also have a poor response to gemcitabine. In control KPC mice, only two of 17 tumours responded to gemcitabine treatment, and this finding is similar to clinical results in human PDAC patients, in whom the response rate is 5% to 10%. When applying IPI-926, an inhibitor of the sonic hedgehog (shh) pathway, depletion of the desmoplastic stroma and of α-SMA positive CAFs was observed. This finding resulted in increased vascularization and more effective drug delivery, with improved overall survival. These data suggest that depletion of stromal tissue and CAFs in PDAC stimulated angiogenesis and enhanced drug delivery\(^{[97]}\). This finding could explain why inhibitors of angiogenesis have failed to significantly improve outcomes in PC, as approaches would potentially result in the decreased delivery of chemotherapeutic agents.

Recently, IPI-926 was applied in a phase I study in combination with oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) (Table 1)\(^{[98]}\). The study was closed early because a separate phase II trial of IPI-926 plus gemcitabine indicated a shorter median survival in patients receiving this treatment.

The desmoplastic stroma, however, does not only form a barrier that reduces tumour perfusion and hampers the effect of chemotherapeutic treatment. Recent data, based on studies on GEMMs, have indicated that the desmoplastic stroma, as a whole, might reduce the ability of PDAC cells to invade the surrounding tissue and metastasize\(^{[99-101]}\). When PKT (Ptf1a\(^{Cre/+}\); LSL-Kras\(^{G12D/+}\); Tgfbr2\(^{−/−}\)) mice developing spontaneous PC were depleted of α-SMA-positive myofibroblasts, more invasive tumours developed and survival was reduced\(^{[99]}\). In agreement with these findings in mice, immunohistochemical scoring of interstitial α-SMA positive cells from 53 resected PDAC specimens revealed that small numbers of α-SMA positive cells were associated with shorter survival\(^{[99]}\). Stromal depletion by deleting shh was examined in the PKCY mouse model, resulting in earlier tumour development and decreased survival\(^{[100]}\). In subsequent
Table 1 Important clinical trials describing drugs that target components of the pancreatic cancer stroma

| Clinical trial | Target | Drug | Results |
|----------------|--------|------|---------|
| Bramhall et al[146], 2002 | ECM | Marimastat: MMP inhibitor | No survival advantage was found in patients receiving marimastat in combination with gemcitabine compared to patients receiving gemcitabine alone |
| Moore et al[147], 2003 | ECM | Bay 12-9566: MMP inhibitor | Phase III trial was closed early because Bay12-9566 treatment was inferior to gemcitabine treatment |
| Strimpakos et al[148], 2013 | ECM | PEGPH20: degradation of hyaluronan | Phase II trial of PEGPH20 administration in combination with gemcitabine showed no significant toxicity. Phase II trials are warranted |
| Lutz et al[149], 2011; Lahera et al[150], 2008 | Immune cells | GVAX: GM-CSF-based immunotherapy | Phase II trial showed that GM-CSF-based immunotherapy was a safe immunotherapeutic approach in combination with chemoradiation therapy. Phase II, multicentre trials are warranted |
| Royal et al[151], 2010 | Immune cells | Ipilimumab: CTLA-4 inhibitor | Phase II trial of administration of ipilimumab did not show an acceptable response as a single-agent therapy |
| Le et al[152], 2013 | Immune cells | Ipilimumab + GVAX | Phase II trial of ipilimumab in combination with GVAX demonstrated an improvement in overall survival compared to patients receiving ipilimumab alone. Phase II trials are warranted |
| Brahmer et al[153], 2012 | Immune cells | BMS-936559: PD1L inhibitor | Phase I trial found no objective response in PC patients receiving BMS-936559 treatment |
| Beatty et al[154], 2013 | Immune cells | CP-870893: CD40 agonist | Phase I trial showed that CP-870893 was well-tolerated in combination with gemcitabine in patients with advanced PDAC, and immune activation was observed. Phase II trials are warranted |
| Ko et al[155], 2015 | Stromal depletion | IPI-926 (saridegib): hedgehog inhibitor | Phase II trial administered IPI-926 in combination with FOLFIRINOX. The study was closed early because a separate trial documented that the patients experienced a shorter median survival |
| Kindler et al[156], 2010 | Angiogenesis | Bevacizumab: VEGF-A inhibitor | Phase III trial of bevacizumab in combination with gemcitabine did not improve overall survival compared to patients receiving gemcitabine alone |
| Kindler et al[157], 2011 | Angiogenesis | Axitinib: inhibitor of VEGF receptors 1, 2 and 3 | Phase III trial of axitinib in combination with gemcitabine did not improve overall survival compared to patients receiving gemcitabine alone |

ECM: Extracellular matrix; MMPs: Matrix metalloproteinases; VEGF: Vascular endothelial growth factor; PC: Pancreatic cancer; PDAC: Pancreatic ductal adenocarcinoma.

experiments, shh deletion resulted in a significantly reduced stroma and the reduction of α-SMA positive myofibroblasts.

When primary human cancer-associated PSCs were treated with the Vitamin D analogue calcipotriol, lipid droplet formation increased and α-SMA expression decreased, resulting in the induction of quiescence in CAFs[102]. To examine the clinical potential of vitamin D receptor activation, calcipotriol was administered to KPC mice together with gemcitabine, resulting in significant reduction of tumour size in 70% of mice, while the intratumoral concentration of gemcitabine triphosphate, the active metabolite of gemcitabine, increased by 500%. The median survival was increased by 57%, supporting the possibility that stromal reprogramming to a more quiescent state, rather than its total ablation, is efficient in PC[102]. Notably, this study indicated that deactivation of CAFs increased the susceptibility of PC cells to chemotherapy. Based on these assumptions, Gundewar et al[103] identified a new agent that could potentially inhibit the anti-therapeutic effects of CAFs. These authors were able to inhibit the proliferation of immortalized human PSCs when cultured with L49H37, a synthetic analogue of curcumin. The L49H37-treated cells were retained in the G0/G1 phase, possibly due to elevated phosphorylation of ERK1/2 and the downregulation of p21.

Taken together, the above studies illustrate the complex role of the desmoplastic tumour stroma in the progression of PC. Most of the initial studies indicated that the desmosplasia and the cells producing it hampered the effect of chemotherapy and promoted PDAC cell proliferation and metastasis. More recent studies, however, have supported the idea that the desmoplastic stroma might form a barrier that reduces the invasion of PDAC cells. Hence, the role of the desmosplasia seems to be context-dependent. Induction of quiescence in CAFs, leading to modulation of the tumour stroma rather than ablation, could be the most promising approach for the future development of treatments targeting tumour desmosplasia in PC.

**Prognostic value of CAF markers**

High "stromal activity", i.e., elevated expression of α-SMA-positive CAFs in the stroma surrounding the cancer cells, had a negative prognostic impact in PDAC patients, as shown in a study of 233 resected PDAC specimens[104]. The significance of high α-SMA expression in the PDAC tumour stroma was later supported by a study of 162 patients[158]. However, as mentioned above, depletion of α-SMA-positive myofibroblasts in the PDAC stroma of Pkt mice was associated with shorter survival[69]. Large amounts of secreted protein acidic and rich in cysteine (SPARC), an alternative CAF marker in PDAC, had negative
prognostic value in PDAC\cite{106-109}. Immunohistochemical characterization of 299 PDAC resection specimens revealed that patients labelled positive for stromal SPARC had a median survival of 15 mo, compared to 30 mo for patients with no stromal SPARC expression\cite{109}. Immunohistochemical characterization of SPARC expression in PC biopsy specimens from 58 non-resectable patients prior to CRT revealed that patient survival was inversely correlated with stromal SPARC expression\cite{108}. High SPARC expression, however, had a negative prognostic impact only in patients treated with adjuvant gemcitabine after resection but not in adjuvant treatment-naive patients\cite{107}.

The desmoplastic stroma in PDAC is not a homogeneous tissue. Different stromal compartments can be more or less active, and the distribution and frequency of different cell types vary in them. The desmoplastic stromal compartments were classified based on in situ hybridization experiments on human PDAC tissues\cite{110}. Messenger RNA expression of 12 genes was scored in the entire tumour stroma, called the panstroma, compared to the stroma in the immediate vicinity of the cancer cells, called the juxtatumoral stroma. Three genes (apolipoprotein C-1, apolipoprotein D and MMP11) were observed in the juxtatumoral stroma but not in stromal cells located distantly from the cancer cells. Further, α-2 macroglobulin was localized to non-neoplastic endothelial cells and the juxtatumoral stroma but not to the peripheral stroma. It was suggested that the juxtatumoral stroma plays a more active role in the invasive process in PDAC\cite{110}. The expression of the above-mentioned genes in PDAC was further evaluated in seven PC samples associated with intraductal papillary mucinous neoplasms (IPMNs), of which two were colloid carcinomas, two were tubular carcinomas, and three were mixed colloid/tubular carcinomas\cite{111}. The three genes were expressed in the juxtatumoral stroma in all areas with tubular carcinoma, but no expression was observed in the juxtatumoral stroma of the two colloid carcinomas. This study also included eight PDAC specimens, two of which had liver metastases. Apolipoprotein C-1 and apolipoprotein D, but not MMP11, were also expressed focally in one of the metastases\cite{111}. These data indicate that the three juxtatumoral markers could be of specific importance for the invasion of pancreaticobiliary-type adenocarcinomas but not necessarily for the implantation of metastatic PC cells in the liver.

Alpha-SMA is routinely used to identify aPSCs and CAFs in PDAC. However, different subsets of CAFs might be present in the PC stroma\cite{82,112}. Mouse models of PC (Rip1Tag2 mice) and breast cancer (4T1 cells injected into BALB/c mice) harboured CAF subpopulations, in which FSP1-positive CAFs in particular showed only minimal overlap with other CAF markers, such as neuron-glial antigen 2 (NG2), α-SMA, and PDGF\cite{82}. A CD10-positive subpopulation of CAFs was identified in human PDAC specimens\cite{112}. They were localized juxtatumorally, in close proximity to PDAC cells in 28 of 83 specimens, and these patients had significantly shorter survival. Additional studies focusing on the possible different roles of CAF subpopulations would be of great interest, as such studies have the potential to cast additional light on the suggested context-dependent functional roles of CAFs in PDAC.

**ROLE OF StromAl ECM COMPONENTS IN THE DEVELOPMENT AND PROGRESSION OF PC**

The desmoplastic stroma in PDAC contains large amounts of ECM molecules (Figure 4). CAFs are responsible for ECM synthesis in PDAC. Many ECM proteins have been described in PDAC, including fibronectin\cite{116,119}, laminin\cite{113,114}, tenascin C\cite{115}, hyaluronan\cite{116-119}, collagen I\cite{117,118,120,121}, collagen III\cite{114,122,123}, collagen IV\cite{114,122,123}, and collagen XIA\cite{124,125}. Increased PC cell death was observed in vitro when cancer cells were detached from the ECM, whereas survival was increased when cancer cells were cultured with laminin or fibronectin\cite{126}. In PC resection specimens, samples with high stromal activity and low collagen deposition were associated with shorter patient survival, whereas the opposite was true for samples with low stromal activity and high collagen deposition\cite{104}. Collagens I and IV induce PC cell migration and metastasis\cite{127,128}. The human PC cell lines BxPC-3 and Panc-1 became more motile when cultured on collagen I-coated dishes, compared to non- fibronectin-, or laminin-I-coated plates\cite{127}. The migratory properties were accompanied by a more mesenchymal phenotype, due to upregulation of N-cadherin, vimentin, and snail\cite{127,129}. Collagen I-induced PC cell migration was demolished after treatment with an inhibitor of c-Jun NH2-terminal kinase (JNK). Inhibition of other signalling pathways, however, did not influence collagen I-induced migration\cite{129}.

**MMPs and degradation of ECM in PC**

ECM breakdown is considered a mandatory step in the processes of tumour invasion and metastasis\cite{130}. The family of matrix metalloproteinases (MMPs) are the enzymes that are most responsible for degrading ECM proteins\cite{131}. ECM turnover is a highly dynamic process, and ECM components are constantly synthesized, predominantly by fibroblasts, and broken down by MMPs. The different MMPs share a similar domain structure, and their activity is regulated by tissue inhibitors of metalloproteinases (TIMPs)\cite{131}. The expression of mRNAs encoding ECM-degrading MMPs was examined in human PC specimens\cite{132}. MMP-2 and MMP-9 were elevated compared to the normal pancreas, and by in situ hybridization, they were particularly
Figure 4  Main components of the tumour stroma in pancreatic cancer. A: Pancreatic cancer (PC) cells, arranged in small groups and duct-like structures, are surrounded by desmoplastic stroma (HE staining); B: PC cells strongly express maspin (maspin immunostaining); C: Using a Sirius red stain, the collagen fibres of the desmoplastic stroma are highlighted; D: Numerous $\alpha$-smooth muscle actin-positive cancer-associated fibroblasts are observed; E: Tumour-infiltrating macrophages (CD163 immunostaining); F: T cells (CD3 immunostaining) are shown; G: Additionally, a few mast cells (tryptase immunostaining); H: neutrophilic granulocytes (myeloperoxidase immunostaining) are present; I: Several newly formed small blood vessels are located in the desmoplastic stroma (CD31 immunostaining).
located in PC cells and spindle-shaped stromal cells (CAFs/aPSCs)\(^{[132]}\). Expression of these MMPs and of MMP13 was later observed in cultured rat PSCs. MMP2 expression was significantly increased when PSCs were culture-activated or stimulated with TGF-β1 and IL-6\(^{[90]}\).

Koshiba et al\(^{[133]}\) examined the role of MMP-2 in human PC resection specimens using gelatine zymography. The MMP-2 activation ratio was significantly higher than in the normal pancreas, and the ratio was significantly higher in high tumour stage specimens (pT3) and in patients with lymph node and distant metastases compared to pT1 tumours without metastasis. Hence, the upregulation of MMP-2 might play a significant role in tumour invasion and metastasis\(^{[133]}\). However, no correlation has been observed between MMP-2 expression and overall survival\(^{[134,135]}\). The prognostic role of MMP2 was not confirmed in a later study that examined the immunohistochemical expression of MMPs 1-3, 7-9, 11, 12, and 14 in resection specimens\(^{[136]}\). Instead, high expression of MMP7 in particular as well as MMP11 was found to be associated with a poor prognosis. Administration of MMP inhibitors, either alone or in combination with gemcitabine, to patients with advanced PDAC has not shown promising results (Table 1)\(^{[137,138]}\).

**ECM deposition increases fluid pressure and impairs drug delivery**

The interstitial fluid pressure (IFP) in organs is typically lower than or at the same level as the intravascular pressure in terminal blood vessels, thereby allowing the delivery and diffusion of solutes and fluid. High IFP might explain the limited delivery of chemotherapeutic drugs into cancer nodules\(^{[117,139]}\). In KPC mice, the ECM compound hyaluronan was present in large amounts in the juxtatumoral stroma and was also deposited around early precursor lesions of PC\(^{[116]}\). The IFP was significantly increased, and hyaluronan contributed to the increase in IFP in PC tumours, as indicated after implanting matrices with PC cells and different concentrations of hyaluronan. Conversely, the IFP was decreased after treatment with PEGPH20, a hyaluronan-degrading enzyme\(^{[116]}\). The increase in IFP was associated with vascular collapses, further contributing to reduced tumour perfusion. PEGPH20 was able to restore functional perfusion of the collapsed vascular structures. Overall, survival improved after the treatment of tumour-bearing mice with a combination of PEGPH20 and gemcitabine\(^{[116,118]}\). Importantly, increased drug delivery to the tumour cells does not necessarily guarantee an increased drug response. When gemcitabine was administered to KPC mice in combination with 3,4,5,6-tetrahydroxuridine (THU), an inhibitor of the gemcitabine-inactivating properties of cytidine deaminase, a significantly increased concentration of the active gemcitabine metabolite was observed in both plasma and tumour biopsies\(^{[148]}\). Surprisingly, higher concentrations of active gemcitabine did not significantly reduce tumour volumes in mice treated with gemcitabine + THU compared to gemcitabine only. Phase I trials of PEGPH20 administration in combination with gemcitabine have been performed, and no significant toxicity has been observed (Table 1)\(^{[141]}\). Therefore, phase II trials are currently planned\(^{[141]}\).

**ROLE OF EMT IN METASTATIC PC**

Epithelial-mesenchymal transition (EMT), originally called epithelial-mesenchymal transformation\(^{[142]}\), is characterized by the loss of epithelial properties and the acquisition of a mesenchymal phenotype. Epithelial cell markers, such as E-cadherin, are downregulated, while the expression of mesenchymal cell markers, such as vimentin, is increased\(^{[143,146]}\). Three types of EMT have been defined: type 1 is associated with implantation of the fertilized ovum, the following embryogenesis, and development of organs, type 2 with tissue regeneration and fibrotic processes, and type 3 with cancer progression and metastasis\(^{[145]}\). The importance of type 3 EMT in the development of metastases in human PC is still debated, and most studies have been performed on animals and cultured human cells\(^{[146]}\). Snail and slug, two transcription factors that repress E-cadherin, were expressed in human PC tissues but not in normal epithelial cells\(^{[147]}\). E-cadherin, fibronectin and vimentin expression was characterized in 34 PC resection specimens using immunohistochemistry\(^{[148]}\). In a subgroup of these specimens, PC cells expressed vimentin and fibronectin and showed downregulation of E-cadherin. These patients had decreased survival, indicating that EMT might be related to a more aggressive cancer type\(^{[148]}\). PKCY mice (Pdx1-Cre; Kras\(^{G12D}\); p53\(^{-/-}\); Rosa\(^{269}\)) mimic human PDAC in that they develop PanINs, primary tumours, and metastases with a morphology similar to that in humans\(^{[144]}\). Further, the pancreatic epithelial cells in PKCY mice could be tracked (YFP\(^{-/-}\)-labelled cells). PC cells that underwent EMT could be identified by their expression of zinc finger E-box-binding homeobox (Zeb1) and the loss of E-cadherin. Zeb1 is an activator of EMT, promoting tumorigenesis\(^{[149]}\). Of the YFP\(^{-/-}\)-labelled cells in the PKCY tumours, 42% underwent EMT\(^{[144]}\). Interestingly, EMT could be observed in PanINs before the onset of tumour formation because YFP\(^{-/-}\)/Zeb1\(^{+}\) cells were already present in 8- to 10-wk-old PKCY mice, when no histological evidence of PDAC was present. At the same stage, circulating pancreatic epithelial cells (YFP\(^{+}\) cells) could be observed in the blood by flow cytometry, and YFP\(^{+}\) cells had seeded to the liver in some PanIN mice. Circulating pancreatic tumour cells from both PanIN and PDAC mice maintained a mesenchymal phenotype, as indicated by the expression of Zeb1 and reduced expression of E-cad, CK19, and EpCAM\(^{[144]}\).
Is EMT associated with the initiation of a stem cell program?

The presence and function of specialized tumour-initiating cells, the so-called cancer stem cells (CSCs), have been controversial\(^{(150)}\). CSCs are defined as malignant cells with stem cell properties, that is, the ability to undergo self-renewal and the potential to differentiate into all of the cell types corresponding to the original tumour. It has been hypothesized that EMT precedes the acquisition of stem cells traits\(^{(145,151,152)}\). In PC, support for this hypothesis has been found in several studies\(^{(153-156)}\). Immunohistochemical aldehyde dehydrogenase (ALDH) expression was detected in 90 of 269 PC resection specimens and was related to reduced overall survival\(^{(153)}\). ALDH-positive PC cells were more tumorigenic than ALDH-negative cells in vitro as well as when injected subcutaneously into the flanks of athymic mice\(^{(157)}\).

Well-described CSC markers in PC include CD24, CD44, and CD133\(^{(157,158)}\). Human PC cells with a CD24\(^+\), CD44\(^+\), epithelial-specific antigen (ESA)\(^+\) phenotype were 100 times more tumorigenic than CD24\(^-\), CD44\(^-\), ESA\(^-\) PC cells when subcutaneously injected into NOD/SCID mice\(^{(157)}\). Similarly, 500 patient-derived CD133\(^+\) pancreatic CSCs were capable of inducing orthotopic tumours in athymic mice, whereas 10\(^6\) CD133\(^-\) tumour cells did not form any tumours\(^{(158)}\). The expression of CD24, CD44, and CD133 relative to EMT was examined in cell cultures, as well as PC resection specimens\(^{(154)}\). The expression of vimentin was correlated positively, and E-cadherin was correlated negatively with the expression of CD24, C44, and CD133, thus supporting the theory that type 3 EMT might be correlated with the initiation of a stem cell program in PC\(^{(154)}\).

Vimentin and urokinase-type plasminogen activator receptor expression was correlated with CD24 and CD44 expression in PC resection specimens\(^{(155)}\). Given the upregulation of mesenchymal markers in PC cells, a functional role of CD133 in PC tumorigenesis was suggested\(^{(156)}\). In vitro knockdown of CD133 with shRNA in the highly migratory human PC cell line Capan1M9 (CD133\(^{hi}\)) generated the cell line shCD133M9, which showed reduced expression of mesenchymal factors, such as slug, N-cadherin, and fibronectin. Moreover, when injected orthotopically into nude mice, shCD133M9 cells were less invasive and produced fewer metastases\(^{(156)}\).

Relationship of the tumour microenvironment with cancer stem cells

Nodal and activin are secreted proteins that belong to the TGF\(\beta\) superfamily, and they are strongly expressed in pancreatic CSCs and PSCs\(^{(159)}\). Inhibition of the nodal/activin pathway reversed CSC self-renewal and tumorigenesis\(^{(159)}\). In a later study, CSCs from human PDAC xenografts were isolated by sphere formation assay, and conditioned media from the cancer cells promoted nodal and activin A expression in PSC\(^{(160)}\), conversely, conditioned media from PSCs resulted in only a small increase in activin expression in PC cells. However, conditioned media from PSCs resulted in increased invasiveness of CSCs through nodal/activin signalling\(^{(160)}\). It was proposed that PSCs might form a niche for CSCs, promoting invasiveness and self-renewal through nodal/activin signalling.

In 3D indirect co-cultures with different human PC cell lines, PSCs enhanced the CSC phenotype, as indicated by increased sphere formation and CSC markers\(^{(95)}\). In this model, each sphere was believed to derive from one single cell. In a xenograft model, human PC cells were transplanted into mice alone or with human PSCs, inducing CD24 and CD326 (EpCAM). The stemness-promoting effect of PSCs was in part attributed to TGF\(\beta\) signalling because TGF\(\beta\) neutralizing antibodies inhibited CSC sphere formation ability and downregulated EMT markers\(^{(99)}\).

Macrophages might also potentiate CSC features in PC\(^{(161)}\). When human sphere-derived CSC-enriched PC cells were injected into nude mice, tumour growth accelerated when co-injected with macrophages. In subsequent co-culture studies in trans-wells, microarray analyses showed upregulation of human cationic antimicrobial protein 18 (hCAP-18) and its cleavage product leucine leucine-37 (LL-37) in macrophages. The expression of hCAP-18/LL-37 in human PDAC was increased compared to the normal pancreas. Serial staining showed that hCAP-18/LL-37 was mainly expressed in CD68\(^+\) macrophages. When CRAMP (the murine homologue of hCAP-18/LL-37)-knockout bone marrow mononuclear cells were transplanted into irradiated KPC mice, tumour formation was less pronounced than in bone marrow cells from wild-type mice\(^{(161)}\). Further, when CSCs were transplanted into wild-type or CRAMP-knockdown mice, tumour formation and CD133 expression were significantly reduced. Chemoresistance in CSCs increased following rLL-37 treatment, in addition to gemcitabine or abraxane, and increased CD133\(^+\) cells were observed. Exposure of M1 macrophages to CSC-conditioned media increased polarization towards the M2 phenotype and upregulation of LL37. This effect could be abolished by blocking nodal/activin/TGF-\(\beta\)1 signalling\(^{(161)}\). Inhibition of the LL37 receptors FPR2 and P2X7R reduced the ability of LL37 treated sphere-derived PDAC cells to form colonies and to invade in vitro, and CD133\(^+\) cells were reduced in number, suggesting that LL37 inhibition could have therapeutic potential. In KPC mice, LL37 receptor inhibitors resulted in decreases in circulating tumour cell numbers and liver metastases\(^{(161)}\).

ROLE OF INFLAMMATORY CELLS IN THE DEVELOPMENT AND PROGRESSION OF PC

The desmoplastic stroma in PDAC contains large...
numbers of inflammatory cells - mainly macrophages, T cells, mast cells, and neutrophilic granulocytes (Figure 4). Inflammatory cells play multiple opposing roles in the progression of PDAC, and as a whole, they represent a double-edged sword in the biology of PC. Some inflammatory cells, particularly cytotoxic CD8+ T cells, act anti-carcinogenically by eliminating PC cells[162]. Others, particularly M2 macrophages, contribute to tumour progression by the synthesis of angiogenic and proliferation-promoting cytokines and chemokines[163,164]

The evolving PC-related immune reaction was characterized in Kras<sup>G12D</sup> mice[165]. These mice express a single mutant Kras allele in progenitor cells and develop early PanIN lesions, followed by the progression through all of the PanIN stages and finally invasive lesions that metastasize. Morphologically, these lesions are similar to their counterparts in the human pancreas[166,167]. The pre-invasive PanIN lesions in Kras<sup>G12D</sup> mice were accompanied by the upregulation of CD45-positive leukocytes in the surrounding stroma[168]. In the early PanIN lesions, the immune response was dominated by immunosuppressive cells, such as macrophages (CD11b<sup>+</sup>), regulatory T cells (Tregs, Foxp3<sup>+</sup>), and myeloid-derived suppressor cells (MDSCs, Gr1<sup>+</sup>, CD11b<sup>+</sup>), but no effector T cell activity was observed, and CD8<sup>+</sup> T cells were scarce. Increased CD8<sup>+</sup> T cells were only found in a subset of advanced cancers[169,165].

CD40 belongs to the superfamily of TNF receptors, and it is expressed in a wide variety of cells, including monocytes, macrophages, B cells, dendritic cells, fibroblasts, endothelial cells, and epithelial cells[166]. CD40 activation is involved in the development of a T cell-dependent antitumour response[167]. In human PDAC and GEMMs of PC, activation of CD40 by agonist antibodies increased the effect of gemcitabine[167], mediated through CD40-activated macrophages (F4/80<sup>+</sup>) in the tumour stroma. In a subsequent phase I study, CP-870,893, a monoclonal antibody specific for F4/80<sup>+</sup> mediated through CD40-activated macrophages (F4/80<sup>+</sup>) to CD4<sup>+</sup> T cells was associated with shorter survival, whereas a high ratio of M1 macrophages to pan-macrophages was associated with longer survival[170]. High levels of CD4<sup>+</sup> T cells or CD8<sup>+</sup> T cells were associated with shorter survival, whereas a high ratio of Tregs (Foxp3<sup>+</sup> and CD4<sup>+</sup>) to CD4<sup>+</sup> T cells was associated with shorter survival. Infiltration of M2 phenotype macrophages (CD163<sup>+</sup> and CD20<sup>+</sup>) had a stronger correlation with lymph node metastasis than pan-macrophages in pancreatic cancer resections[171,172]. Similarly, a large number of M2 macrophages was correlated with increased lymphatic vessel density and poor prognosis. Hence, M2 macrophages might indicate poor prognosis, in part due to increased lymph node metastases[173,172]. This connection could be partially explained by the production of vascular endothelial growth factor (VEGF)-C by macrophages, leading to an increase in the number of pertumoral lymph vessels[169,173,174].

Macrophage-stellate cell crosstalk plays an important role in PC fibrogenesis. Lipopolysaccharide (LPS)-activated macrophages induced ECM synthesis in cultured rat and human PSCs through TGF-β signalling[175]. Quiescent PSCs became activated when co-cultured with macrophages[176]. Conversely, macrophages increased their cytokine production in the presence of PSCs. PSCs isolated from patients (normal pancreas and PC) predominantly expressed Th2 cytokines (IL4 and IL13) and promoted macrophage polarization towards M2[177]. Macrophages induced EMT in PC cells in co-culture experiments of PC cells with M2 macrophages, through Toll-like receptor 4 (TLR4)/IL-10 signalling[178]. Modulation of macrophage polarization from the immunosuppressive M2 phenotype to the tumour-inhibiting M1 phenotype could represent a novel strategy in the treatment of PC. Furthermore, the expression of histidine-rich glycoprotein (HRG) was increased in Panc02 mouse pancreatic tumour cells when transduced with a lentiviral vector encoding human HRG[179]. When implanted into WT mice, HRG<sup>+</sup> orthotopic Panc02 pancreatic tumours grew slower and had fewer metastases, and these effects were mediated through the induction of macrophage polarization from M2 towards M1[179]. Macrophages might induce gemcitabine resistance in PC[180]. In an in vitro study in which PC cells were co-cultured with macrophages, PC cell apoptosis and caspase-3 pathway activation were reduced during gemcitabine treatment in the presence of macrophages. Further, increased response to gemcitabine was observed in CCR2<sup>-/-</sup> mice, characterized by reduced macrophage infiltration and activation. Macrophages could induce gemcitabine resistance in a paracrine manner because they were associated with increased cytidine deaminase in PC cells[180].

**Mast cells**

Mast cells have mainly been assigned roles in allergy and autoimmunity, but they might also play a role in...
PC biology. Mast cell infiltration has been observed in PC, and their numbers are correlated with the number of lymph node metastases\(^{169}\). Mast cells are increased in human PC specimens compared to the normal pancreas, and this increase is most pronounced in advanced grade tumours\(^{181}\). High mast cell infiltration held unfavourable prognostic value with reduced survival\(^{181,182}\). Mast cell distribution has been examined in two main PC compartments: the intratumoral compartment and peritumoral, non-neoplastic tissue. Each of these compartments was further subdivided into central and border regions\(^{183}\). High mast cell counts in the intratumoral border zone only were associated with worse overall survival\(^{183}\).

In mast cell cultures, the addition of conditioned media from PC cell cultures increased migratory mast cell activity, and mast cell-conditioned media induced PC cell proliferation and migration\(^{181}\). Using the genetically engineered K-rasG12V mouse model, which spontaneously develops chronic pancreatitis, PanINs, and invasive PC, mast cell infiltration was found to be an early event, occurring in chronic pancreatitis and early PanINs. Injection of PC cells into Kit\(^{+}\)sh/wsh-sh mast cell-depleted mice reduced tumour growth and increased survival. “Normal” tumour growth was restored when bone marrow-derived cultured mast cells were injected\(^{182}\). When mast cells were incubated with conditioned media from PC cells, PSCs, and ductal epithelial cells, only the medium from PC cells induced mast cell migration, and mast cell-conditioned media increased PC cell and PSC proliferation\(^{184}\). Additionally, co-cultures of mast cells with either PC cells or PSCs resulted in mast cell activation, and neutralization of IL-13 and tryptase reduced mast cell activity. Further, tumour-bearing mice treated with AMD3100, a CXCR4 antagonist that mediates mast cell migration, resulted in a 50% decrease in tumour volume and increased overall survival\(^{181}\).

These findings illustrate the potential importance of mast cells in PC progression and the possible benefit of the future development of mast cell-targeted therapies in PC. To date, however, such therapies do not play a role in clinical practice. Moreover, it has been reported in GEMMs in which mast cells were absent (Pdx1-Flp; FSF-Kras\(^{G12D/+}\); Cpa3\(^{-/-}\) mice) that the formation, number, and stage of PanINs at 9 mo of age were not different from Pdx1-Flp-FSF-Kras\(^{G12D/+}\) controls, which frequently showed mast cells; at 12 mo, PDAC formation was observed in both groups\(^{185}\).

**Lymphocytes**

In PC, regulatory T cells (Tregs, CD4\(^{+}\) and CD25\(^{+}\)) are increased in peripheral blood, as well as in the tumour microenvironment\(^{186}\). Treg increment in the stroma induces immune invasion in PC because Tregs suppress the antitumour immune response through inhibitory cytokines, such as IL-10 and TGF-β, thereby influencing cytotoxic CD8\(^{+}\) T cell activity\(^{186}\).

When the TGF-β-expressing PC cell line PAN02 was subcutaneously injected into C57BL/6 mice, CD4\(^{+}\) CD25\(^{+}\) Tregs in tumour-draining lymph nodes were increased\(^{187}\). When Rag-1\(^{-/-}\) mice lacking CD4 and CD8 T cells were injected with CD4\(^{+}\) CD25\(^{+}\) cells from normal mice, with or without a subsequent injection of PAN02 cells, elevation of Foxp3 signals (a specific marker for Tregs) was only observed in the tumour-draining lymph nodes of PAN02 challenged mice. This outcome was inhibited by TGF-β neutralizing antibodies, suggesting that PC cells promote the upregulation of Tregs through TGF-β\(^{187}\). Furthermore, upregulation of addressins in intratumoral endothelial cells might selectively recruit Tregs, and Treg migration could be suppressed by selective addressin antagonism\(^{186}\).

Lymphocyte infiltration of distinct stromal PC compartments varies: the frequencies of CD8\(^{+}\) T cells, FoxP3\(^{+}\) regulatory T cells, CD20\(^{+}\) B cells, and CD56\(^{+}\) natural killer cells in the juxtatumoral compartments were all very low compared to the frequencies in the panstroma\(^{189}\). In this tissue micro-array (TMA) study of PC resection specimens and other pancreatobiliary diseases, CD68\(^{+}\) macrophages, in contrast, were more frequent juxtatumorally. No significant variation was observed in the distribution of CD4\(^{+}\) T cells or neutrophils. Patients with more extensive juxtatumoral CD8\(^{+}\) T cell infiltration had improved survival\(^{189}\). PSCs, through cytokine and chemokine signalling, were shown to reduce the migration of CD8\(^{+}\) T cells to the juxtatumoral stromal compartment in PC, suggesting an immunosuppressive role of PSCs in PC.

Luminex multiplex immunoassays were used to examine the expression of cytokines and chemokines in cultured PC-derived PSC lines\(^{189}\). Compared to human foetal primary pancreatic fibroblasts, PSCs expressed high levels of the MDSC-promoting cytokines IL-6, VEGF, macrophage colony-stimulating factor (M-CSF), stromal cell-derived factor 1 (SDF-1), and monocyte chemoattractant protein-1 (MCP-1). In agreement, culture of peripheral blood mononuclear cells (PBMCs) with PSC supernatant promoted MDSC differentiation, which in turn reduced T cell proliferation. MDSCs expressed CD11b and CD33 and inhibited tumour-specific immune responses by suppressing CD8\(^{+}\) T cells\(^{190}\).

As indicated in the above sections, the PC tumour environment displays several immunosuppressive properties, which makes immunotherapeutic approaches challenging. Immune checkpoint therapy is a promising strategy that targets the endogenous, immunosuppressive regulatory pathways in T cells described above. Promising results have been obtained, for example, in the treatment of malignant melanoma, and three immune checkpoint agents have been approved for this disease by the United States Food and Drug Administration\(^{191}\). Similar strategies are under investigation for PC treatment, but so far have achieved...
only limited success, for example, in a phase II trial of the cytotoxic T lymphocyte antigen 4 (CTLA4)-blocking antibody ipilimumab (Table 1)[192]. PC cells express colony-stimulating factor 1 (CSF1), whereas the CSF1 receptor (CSF1R) is predominantly expressed in the tumour stroma, and inhibition of CSF1R in a mouse model of PDAC resulted in the depletion of tumour-associated macrophages, enhancement of cytotoxic T cell infiltration, and reduced tumour progression[193]. However, the effects of ipilimumab therapy in the phase II trial were rather limited, which could be attributed to the synchronous induction of the T-cell checkpoint molecules CTLA4 and programmed death-ligand 1 (PDL1). When PDAC mice were treated with a combination of CSF1R inhibitors and PD1 receptor or CTLA4 antagonists, stronger tumour regression was observed when these drugs were used alone. Hence, CSF1/CSF1R inhibition might have the potential to improve the effects of checkpoint-based immunotherapy in PC[193]. A phase I trial examined the effect of the PDL1-inhibiting antibody BMS-936559 in patients with selected advanced cancers, including PDAC[194]. No objective response in patients with pancreatic cancer was observed compared to patients with ovarian cancer, renal-cell cancer, melanoma, and non-small-cell lung cancer.

ROLE OF ENDOTHELIAL CELLS AND ANGIogenesis IN THE DEVELOPMENT AND PROGRESSION OF PC

In PC, as in many other cancers, the need for oxygen and nutrients increases during tumour growth, leading to the synthesis of new blood vessels through the proliferation of endothelial cells in the pre-existing blood vessels, a process called angiogenesis[195]. Simultaneously, proteolytic enzymes break down the ECM[196]. Despite this angiogenesis, direct intratumoral measurement of oxygenation has revealed significant intratumoral hypoxia in PC[197]. Hypoxic conditions have also been described in the tumour stroma, as evidenced by the upregulation of hypoxia-inducible factors in CAFs[198,199].

Angiogenesis in PC is regulated by a complex interplay between different cell types in the tumour stroma. Under hypoxia (0.75%-1% O₂), compared to normoxic (21% O₂), conditions, cultured PSCs increased their production of collagen I and the proangiogenic vascular endothelial growth factor (VEGF)[200,201]. VEGF-synthesis in PSCs was also demonstrated by immunofluorescence in PC specimens[200]. Conditioned media of hypoxia-cultured PSCs induced the proliferation and migration of endothelial cells and induced angiogenesis in vitro as well as in vivo in mice[200]. The proliferation of endothelial cells in cell cultures was increased by up to 47% after treatment with PSC supernatant, whereas PC cell supernatant reduced endothelial cell growth[201]. Furthermore, CD31 was upregulated in primary tumours of BALB/c mice co-injected with human PC cells and human PSCs compared to mice injected with PC cells only[191]. In addition to PSCs, VEGF is predominantly expressed in PC cells and endothelial cells, as well as in tumour-associated macrophages[202,203]. VEGF is an important unfavourable prognostic marker in PC[204]. Multivariate analyses have revealed a significant association between high VEGF and PC recurrence, and it has been suggested that VEGF-promoted metastasis might in part be the cause of this early recurrence[202,205].

TNP-470 is a synthetic analogue of the fungus-derived bioactive agent fumagillin, which inhibits endothelial cell proliferation[206]. TNP-470 significantly reduced tumour size and spread in orthotopic xenograft models of PC in mice[207]. This early study indicated that therapies targeting angiogenesis have potential in PC. Administration of small doses of TNP-470 (30 mg/kg) or gemcitabine (50 mg/kg) alone had no significant effect, but a combination of these therapies reduced tumour growth and metastases and improved median survival[208]. In a phase II clinical trial, the recombinant, humanized monoclonal VEGF antibody bevacizumab was administered in combination with gemcitabine to 52 advanced-stage PC patients[209]. A response rate of 21% and a median survival of 8.8 mo were observed, which were considered superior to gemcitabine alone. The following phase III trial, using gemcitabine plus bevacizumab compared to gemcitabine plus placebo in 602 patients with advanced PC, unfortunately did not show any significant efficacy of this regimen, however (Table 1)[210]. Exploiting a similar strategy, inhibition of VEGF receptors with axitinib in combination with gemcitabine did not improve overall survival in a phase III trial in patients with advanced PDAC[211]. In all, targeting VEGF signalling alone appears to be an ineffective strategy in the treatment of PDAC.

CLINICAL IMPLICATIONS OF MODULATING THE PANCREATIC CANCER STROMA

The median survival after the diagnosis of PC is only 8 mo[212]. Surgical resection offers the only hope for significantly prolonged survival, but even after surgery, the median survival is only 21 mo. Surgical resection can only be offered to approximately 20% of patients because the remaining patients present with advanced disease at the time of diagnosis. The current standard of care for PC patients is the nucleoside analogue gemcitabine[213]. However, the survival benefit of gemcitabine treatment is minimal, and better therapeutic strategies are needed. FOLFIRINOX was found to be associated with a survival advantage compared to gemcitabine in a clinical trial of metastatic PC[214]. Pre-clinical studies have indicated that therapies
targeting the pancreatic cancer stroma could offer hope for better prognoses for PC patients, but so far, it has not been possible to translate these promising results to a clinical setting\textsuperscript{215,216}. In Table 1, we summarize important clinical trials describing drugs that target components of the pancreatic cancer stroma.

**CONCLUSION**

PC is one of the most aggressive known cancer types, and its management remains highly challenging. Gemcitabine, the standard chemotherapeutic drug used in PC, has only a limited effect on patient survival\textsuperscript{213}. Therefore, new treatment strategies, targeting for example the PC stroma, are highly warranted. Because of the complex interplay of the central components of the tumour stroma - cancer-associated fibroblasts (CAFs), extracellular matrix, and inflammatory and endothelial cells - it is often ineffective to use a treatment strategy that blocks single isolated factors. Early studies suggested that large numbers of peritumoral CAFs indicated a poor prognosis in PC\textsuperscript{104}, whereas more recent data have indicated that the depletion of CAFs promotes tumour aggressiveness\textsuperscript{99,100}. The significance of the desmoplastic stroma might be context-dependent during PC progression. Stromal reprogramming, such as the induction of quiescence in aPSCs/CAFs or the antagonism of stromal growth factors, rather than as the induction of quiescence in aPSCs/CAFs or the antagonism of stromal growth factors, rather than during PC progression. Stromal reprogramming, such as...
cycle arrest in hepatic stellate cells through its reducing activity. J Biol Chem 2001; 276: 4059-4059 [PMID: 11509553 DOI: 10.1074/jbc.M100975200]

84 Shimizu K, Kobayashi M, Tahara J, Shiratori K. Cytokines and peroxisome proliferator-activated receptor gamma ligand regulate phagocytosis by pancreatic stellate cells. Gastroenterology 2005; 128: 2105-2118 [PMID: 15940641 DOI: 10.1053/j.gastro.2005.03.025]

85 Wehr AV, Furth EE, Sanger V, Blair IA, Yu KH. Analysis of the human pancreatic stellate cell secreted proteome. Pancreas 2011; 40: 557-566 [PMID: 21499210 DOI: 10.1097/MPA.0b013e318212e4af]

86 Marrache F, Pendyala S, Bhagat G, Betz KS, Song Z, Wang TC. Role of bone marrow-derived cells in experimental chronic pancreatitis. Gut 2008; 57: 1113-1120 [PMID: 18367560 DOI: 10.1136/gut.2007.143271]

87 Scarlett CJ, Colvin EK, Pinese M, Chang DK, Morey AL, Musgrove EA, Pajic M, Apte M, Henshall SM, Sutherland RL, Kench GJ, Blankin AV. Recruitment and activation of pancreatic stellate cells from the bone marrow in pancreatic cancer: a model of tumor-host interaction. PLoS One 2011; 6: e26088 [PMID: 22202519 DOI: 10.1371/journal.pone.0026088]

88 Lin WR, Inatomi O, Lee CY, Kallin YN, Otto WR, Jeffery R, Poulsom R, Alison MR. Bone marrow-derived cells contribute to cerulein-induced pancreatic fibrosis in the mouse. Int J Exp Pathol 2012; 93: 130-138 [PMID: 22283686 DOI: 10.1111/j.1365-2613.2011.00804.x]

89 Scarlett CJ. Contribution of bone marrow derived cells to the pancreatic tumor microenvironment. Front Physiol 2013; 4: 56 [PMID: 23531764 DOI: 10.3389/physiol.2013.00056]

90 Akita S, Kabota K, Kobayashi A, Misawa R, Shimizu A, Nakata T, Yokoyama T, Takahashi M, Miyagawa S. Role of bone marrow cells in the development of pancreatic fibrosis in a rat model of pancreatitis induced by a choline-deficient/ethionine-supplemented diet. Biochem Biophys Res Commun 2012; 420: 743-749 [PMID: 22465012 DOI: 10.1016/j.bbrc.2012.03.060]

91 Pan JJ, Oh SH, Lee WC, Petersen BE. Bone marrow-derived progenitor cells could modulate pancreatic cancer tumorigenesis via peritumoral microenvironment in a rat model. Oncol Rep 2009; 17: 339-345 [PMID: 19544970 DOI: 10.3727/096504009788428424]

92 Direkez NC, Hodivala-Dilke K, Jeffery R, Hunt T, Poulsom R, Oukrif D, Alison MR, Wright NA. Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res 2004; 64: 8492-8495 [PMID: 15574751]

93 Bellini A, Mattoli S. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor cell, in reactive and reparative fibroses. Lab Invest 2007; 87: 858-870 [PMID: 17607298 DOI: 10.1038/labinvest.3700654]

94 Pilling D, Fan T, Huang D, Kaul B, Gomer RH. Identification of markers that distinguish monococyte-derived fibrocytes from monocytes, macrophages, and fibroblasts. PLoS One 2009; 4: e745 [PMID: 19836419 DOI: 10.1371/journal.pone.0007475]

95 Augsten M. Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment. Front Oncol 2014; 4: 62 [PMID: 24734219 DOI: 10.3389/fonc.2014.00062]

96 Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392-401 [PMID: 16572188 DOI: 10.1038/nrc1877]

97 Öhudson L, Elyada E, Tuveson D. Fibroblist heterogeneity in the cancer wound. J Exp Med 2014; 211: 1503-1523 [PMID: 25071162 DOI: 10.1084/jem.20140692]

98 Chang HY, Chi JT, Dudoit S, Bondre C, van de Rijn M, Botstein D, Brown PO. Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci USA 2002; 99: 12877-12882 [PMID: 12297622 DOI: 10.1073/pnas.162488599]

99 Strutz F, Okada H, Lo CW, Danoff T, Carone RL, Tomaszewski JE, Neilson EG. Identification and characterization of a fibroblast marker: FSP1. J Cell Biol 1995; 130: 393-405 [PMID: 7615639 DOI: 10.1083/jcb.130.2.393]

100 Zechner D, Knapp N, Bobrowski A, Radecke T, Genz B, Vollmar B. Diabetes increases pancreatic fibrosis during chronic inflammation.
Exp Biol Med (Maywood) 2014; 239: 670-676 [PMID: 24719378 DOI: 10.1177/15353704124527890]

Boomershine CS, Chamberlain A, Kendall P, Afsar-Sharif AR, Huang H, Washington MK, Lawson WE, Thomas JW, Blackwell TS, Bhownik NA. Autoimmune pancreatic cysts results from loss of TGFbeta signalling in S100A4-positive dextrin cells. Gut 2009; 58: 1267-1274 [PMID: 19625278 DOI: 10.1136/gut.2008.170779]

Sugimoto H, Mundel TM, Kieran MW, Kalluri R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther 2006; 5: 1640-1646 [PMID: 17106243 DOI: 10.4161/cbt.5.12.3354]

Farrow B, Rowley D, Dang T, Berger DH. Characterization of tumor-derived pancreatic stellate cells. J Surg Res 2009; 157: 96-102 [PMID: 19726060 DOI: 10.1016/j.jss.2009.03.064]

Ikenaga N, Ohuchida K, Mizumoto K, Yu J, Fujita H, Nakata K, Ueda J, Sato N, Nagai E, Tanaka M. S100A4 mRNA is a diagnostic and prognostic marker in pancreatic carcinoma. J Gastrointest Surg 2009; 13: 1852-1858 [PMID: 19653048 DOI: 10.1007/s11605-009-0978-4]

Tsukamoto N, Egawa S, Akada M, Abe K, Saiki Y, Kaneko N, Yokoyama S, Shima K, Yamamura A, Motoi F, Abe H, Hayashi H, Ishida K, Morimori T, Tabata T, Kondo E, Kanai N, Gu Z, Sunamura M, Unno M, Horii A. The expression of S100A4 in human pancreatic cancer is associated with invasion. Pancreas 2013; 42: 1027-1033 [PMID: 23851436 DOI: 10.1097/MPA.0b013e3182880467]

Mahon BC, Paril B, Bhakta V, Chelala C, Caulee K, Harada T, Lemoine NR. S100A4 correlates to the suppression of BNIP3 expression, chemoresistance, and inhibition of apoptosis in pancreatic cancer. Cancer Res 2007; 67: 6786-6795 [PMID: 17638890 DOI: 10.1158/0008-5472.CAN-07-0440]

Hinz B. Formation and function of the myofibroblast during tissue repair. J Invest Dermatol 2007; 127: 526-537 [PMID: 17299435 DOI: 10.1038/sj.jid.5700613]

Kloppel G, Detlefsen S, Feyerabend B. Fibrosis of the pancreas: the tissue injury damage and the resulting pattern. Virchows Arch 2004; 445: 1-8 [PMID: 15138818 DOI: 10.1007/s00428-003-0598-0]

Bachem MG, Schünemann M, Ramadani M, Siech M, Beger H, Bueck A, Zhou S, Schmid-Kotasa A, Adler G. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 2005; 128: 907-921 [PMID: 15825074 DOI: 10.1053/j.gastro.2004.12.036]

Hwang RF, Moore T, Arumugam T, Al-Assar O, Ramachandran V, Amos KD, Sherman MH, Plunkett W, Egorin M, Hruban RH, Haddad N, Al-Assar O, Nofal N, Haddad P. Human Pancreatic Cancer-Associated Stellate Cells Remain Activated after in vivo Chemoradiation. Front Oncol 2014; 4: 102 [PMID: 24847445 DOI: 10.3389/fonc.2014.00102]

Olve KP, Jacobetz MA, Davidson CJ, Gopinathana A, McIntyre D, Hones D, Madhu B, Goldbragen MA, Caldwell ME, Allard D, Frese KK, Demicola G, Feig C, Comb C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Rücker F, Grützmann R, Pilarsky C, Izzadregé K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, Hruban RH, Whitebread N, McGovern K, Adams J, Iacobuzio-Donahue C, Griffiths J, Tuveson DA. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324: 1457-1461 [PMID: 19469696 DOI: 10.1126/science.1171362]

Ko AH, LoConte N, Temporo MA, Walker EJ, Kate Kelley R, Lewis S, Chang WC, Kantofoé E, Vannier MW, Catenacci DV, Venook AP, Kindler HL. A Phase I Study of FOLFIRINOX Plus IP1-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas 2016; 45: 370-375 [PMID: 26390428 DOI: 10.1097/MPA.0000000000000458]

Özdemir BC, Penteche-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Lakhal H, Sugimoto H, Kahler C, Novitsky SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Lin H, Moses HL, Weaver VM, Maitra A, Allison JP, LeBluë VS, Kalluri R. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreatic cancer with reduced survival. Cancer Cell 2014; 25: 719-734 [PMID: 24856586 DOI: 10.1016/j.ccr.2014.04.005]

Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra S, Dekleva EN, Saunders T, Becerra CP, Tattersall IW, Westphalen CB, Kikutowski J, Fernández-Barrena MG, Fernández-Zapico ME, Iacobuzio-Donahue C, Olve KP, Stanger BZ. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 2014; 25: 735-747 [PMID: 24856585 DOI: 10.1016/j.ccr.2014.04.021]

Gore J, Kore C. Pancreatic cancer: friend or foe? Cancer Cell 2014; 25: 711-712 [PMID: 24937454 DOI: 10.1016/j.ccr.2014.05.026]

Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, Collisson EA, Connor F, Van Dyke T, Kozlov S, Martin P, Tseng TW, Dawson DW, Donahue TR, Masamune A, Shimosegawa T, Apte MV, Wilson JS, Ng B, Lau SL, Gunton JE, Wahl GM, Hunter T, Drebina JA, O’Dwyer PJ, Liddle C, Tuveson DA, Downes M, Evans RM. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 2014; 159: 80-93 [PMID: 25255922 DOI: 10.1016/j.cell.2014.08.007]

Gundewar C, Ansari D, Tang L, Wang Y, Liang G, Rosendahl AH, Saleem MA, Andersson R. Antiangiogenic effects of curcumin analog L49H37 in pancreatic stellate cells: a comparative study. Ann Gastroenterol 2015; 28: 391-398 [PMID: 26129848]

Erkan M, Michalski CW, Rieder S, Reiser-Erkan C, Abiatiari I, Kolb A, Giese NA, Esposito I, Friess H, Kleeff J. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol 2008; 6: 1155-1161 [PMID: 18639493 DOI: 10.1016/j.cgh.2008.07.004]

Sinn M, Denkert C, Striefler JK, Pelzer U, Stielzer JM, Bahra M, Lohneis P, Dörken B, Oettle H, Riess H, Sinn BV. α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study. Br J Cancer 2014; 111: 1917-1923 [PMID: 25314063 DOI: 10.1038/bjc.2014.495]

Guwadh I, Kleeff J, Adwan H, Giese NA, Wente MN, Giese T, Büchner MW, Berger MR, Friess H. Osteoectin influences growth...
and invasion of pancreatic cancer cells. *Ann Surg* 2005; 242: 224-234 [PMID: 16041213 DOI: 10.1097/01.sla.0000178166.45848.68]

107 Sinn M, Sinn BV, Strieter JK, Lindner JL, Steiler JM, Lohnheis P, Bischoff S, Bläker H, Pelzer U, Bahra M, Dietel M, Dörken B, Oertle D, Hohenberger F, Denkert C. SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. *Ann Oncol* 2014; 25: 1025-1032 [PMID: 24562449 DOI: 10.1093/annonc/mdu084]

108 Mantoni TS, Schendel RR, Rödel F, Niedobitek G, Al-Assar O, Masamune A, Brunner TB. Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma. *Cancer Biol Ther* 2008; 7: 1806-1815 [PMID: 18787407 DOI: 10.4161/cbt.7.11.6846]

109 Infante JR, Matsubayashi H, Sato N, Tonascia J, Klein AP, Riall TA, Yeo C, Iacobuzio-Donahue C, Goggins M. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. *J Clin Oncol* 2007; 25: 319-325 [PMID: 17325047 DOI: 10.1200/JCO.2006.07.8824]

110 Iacobuzio-Donahue CA, Ryu B, Hruban RH, Kern SE. Exploring the host desmoplastic response to pancreatic cancer: gene expression of stromal and neoplastic cells at the site of primary invasion. *Am J Pathol* 2002; 160: 91-99 [PMID: 11786403 DOI: 10.1016/S0002-9440(10)64353-2]

111 Ricci F, Kern SE, Hruban RH, Iacobuzio-Donahue CA. Stromal responses to carcinomas of the pancreas: juxtatumoral gene expression conforms to the infiltrating pattern and not the biologic subtype. *Cancer Biol Ther* 2005; 4: 302-307 [PMID: 15876873 DOI: 10.4161/cbt.4.3.15013]

112 Ikenaga N, Ohuchida K, Mizumoto K, Cui L, Kayashima T, Morimatsu K, Moriyama T, Nakata K, Fujita H, Tanaka M. CD10+ pancreatic stellate cells enhance the progression of pancreatic cancer. *Gastroenterology* 2010; 139: 1041-1051, 1051.e8 [PMID: 20685603 DOI: 10.1053/j.gastro.2010.05.084]

113 Mollenhauer J, Roether I, Kern HF. Distribution of extracellular matrix proteins in pancreatic ductal adenocarcinoma and its influence on tumor cell proliferation in vitro. *Pancreas* 1987; 2: 14-24 [PMID: 3554225 DOI: 10.1097/00006676-198701000-00003]

114 Linder S, Castaños-Velez E, von Rosen A, Biberfeld P. Immuno-histochemical expression of extracellular matrix proteins and adhesion molecules in pancreatic carcinoma. *Hepatogastroenterology* 2001; 48: 1321-1327 [PMID: 11677955]

115 Esposito I, Penzel R, Chab-Harrarce M, Baracena U, Bergmann F, Riedl S, Kayed H, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, Kleeff J, Organ-, inflammation- and cancer specific transcriptional fingerprints of pancreatic and hepatic stellate cells. *Mol Cancer* 2010; 9: 88 [PMID: 20416024 DOI: 10.1186/1476-4598-9-88]

116 García-Pravia C, Galván JA, Gutiérrez-Corral N, Solar-García L, García-Pérez E, García-Ocaña M, Del Amo-Fribaren J, Menéndez-Rodríguez P, García-García J, De los Tojos Y, Simón-Buela L, Barneo L. Overexpression of COL11A1 by cancer-associated fibroblasts: clinical relevance of a stromal marker in pancreatic cancer. *PLoS One* 2013; 8: e78327 [PMID: 24194920 DOI: 10.1371/journal.pone.0078327]

117 Vaquero EC, Edderkouai M, Nam KJ, Gukovsky I, Pandol SJ, Gukovskyia AS. Extracellular matrix proteins protect pancreatic cancer cells from death via mitochondrial and nonmitochondrial pathways. *Gastroenterology* 2003; 125: 1188-1202 [PMID: 14517801 DOI: 10.1016/S0016-5085(03)01203-4]

118 Shintani Y, Hollingsworth MA, Wheelock MJ, Johnson KR. Collagen I promotes metastasis in pancreatic cancer by activating c-Jun NH(2)-terminal kinase 1 and up-regulating N-cadherin expression. *Cancer Res* 2006; 66: 11745-11753 [PMID: 17178870 DOI: 10.1158/0008-5472.CAN-06-2322]

119 Öhlund D, Franklin O, Lundberg E, Lundin C, Sund M. Type IV collagen stimulates pancreatic cancer cell proliferation, migration, and inhibits apoptosis through an autocrine loop. *BMJ Cancer* 2013; 13: 154 [PMID: 23530721 DOI: 10.1186/1471-2407-13-154]

120 Shields MA, Dangi-Garimella S, Kranz SB, Bentrem DJ, Munshi HG. Pancreatic cancer cells respond to type I collagen by inducing sial expression to promote membrane type 1 matrix metalloproteinase-dependent collagen invasion. *J Biol Chem* 2011; 286: 10495-10504 [PMID: 21288898 DOI: 10.1074/jbc.M110.195628]

121 Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. *Nature* 1980; 284: 67-68 [PMID: 6243750 DOI: 10.1038/28467a0]

122 Stetler-Stevenson WG, Liotta LA, Kleiner DE. Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. *FASEB J* 1993; 7: 1434-1441 [PMID: 8262328]

123 Gress TM, Möller-Pillasch F, Lerch MM, Friess H, Büchler M, Adler G. Expression and in-situ localization of genes coding for matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic cancer. *Cancer Res* 2001; 61: 1041-1051, 1051.e8 [PMID: 1178870 DOI: 10.1158/0008-5472.CAN-06-2322]

124 Singh N, Das P, Datta Gupta S, Sahni P, Pandey RM, Gupta S, Chauhan SS, Saraya A. Prognostic significance of extracellular matrix degrading enzymes-cathepsin L and matrix metalloproteinases-2 (MMP-2) in human pancreatic cancer. *Cancer Invest* 2013; 31:
135 Määtä M, Soini Y, Liakka A, Autio-Harmainen H. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. *Cancer Clin Res* 2000; 6: 2726-2734 [PMID: 10914717]

136 Jones LE, Humphreys MJ, Campbell F, Neoptolemos JP, Boyd MT. Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. *Cancer Clin Res* 2004; 10: 2882-2845 [PMID: 15102692 DOI: 10.1186/1551-7042-CCR-1157-03]

137 Moore MJ, Hammond J, Dancey J, Eisenberg PD, Dagenais M, Fields A, Hagan K, Greenberg B, Colwell B, Zee B, Tu D, Ottaway J, Humphrey R, Seymour L. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 2003; 21: 3296-3302 [PMID: 12947065 DOI: 10.1200/JCO.2003.02.098]

138 Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Miyazaki Y, Tsukasa K, Matsubara S, Yoshimitsu M, Weinberg RA. The basics of epithelial-mesenchymal transition. *FASEB J* 2009; 23: 2832-2845 [PMID: 19342579 DOI: 10.1096/fj.08-127593]

139 Neesse A, Frese KK, Bapiro TE, Nakagawa T, Sternlicht MD, Seeley TW, Pilarsky C, Jodrell DL, Spong SM, Tuveson DA. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. *Cell Cycle* 2014; 13: 349-358 [PMID: 23846926]

140 Greenberg B, Hay ED. Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells. *J Cell Biol* 1982; 95: 333-339 [PMID: 7142291 DOI: 10.1083/jcb.95.1.333]

141 Morris HT, Machesky LM. Actin cytoskeletal control during epithelial to mesenchymal transition: focus on the pancreas and intestinal tract. *Br J Cancer* 2015; 112: 613-620 [PMID: 25611303 DOI: 10.1038/bjc.2015.658]

142 Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister B, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Poljak K, Brisken C, Yang J, Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell* 2008; 133: 704-715 [PMID: 18485877 DOI: 10.1016/j.cell.2008.03.027]

143 Rasheed ZA, Yang J, Wang Q, Kovalski J, Freed I, Murter C, Hong SM, Koosrta JB, Rajeshkumar NV, He X, Goggins M, Iacobuzio-Donahue C, Berman DM, Laheru D, Jimeno A, Hidalgo M, Maitra A, Matsui W. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. *J Natl Cancer Inst* 2010; 102: 340-351 [PMID: 20164446 DOI: 10.1093/jnci/djp535]

144 Zhang Y, Wei J, Wang H, Xue X, An Y, Tang D, Yuan Z, Wang F, Wu J, Zhang J, Miao Y. Epithelial mesenchymal transition correlates with CD24+CD44+ and CD133+ cells in pancreatic cancer. *Oncol Rep* 2012; 27: 1599-1605 [PMID: 22322379 DOI: 10.3892/or.2012.1681]

145 Lee SH, Kim H, Hwang JH, Shin E, Lee HS, Hwang DW, Cho JY, Yoon YS, Han HS, Cha BH. CD24 and S100A4 expression in resectable pancreatic cancers with earlier disease recurrence and poor survival. *Pancrates* 2014; 43: 380-388 [PMID: 24622067 DOI: 10.1097/MPA.000000000000097]

146 Ding Q, Miyazaki Y, Tsukasa K, Matsubara S, Yoshimitsu M, Takao S. CD133 facilitates epithelial-mesenchymal transition through interaction with the EREG pathway in pancreatic cancer metastasis. *Mol Cancer* 2014; 13: 15 [PMID: 24468059 DOI: 10.1186/1476-4598-13-15]

147 Li C, Heidt DG, Dalera B, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM. Identification of pancreatic cancer stem cells. *Cancer Res* 2007; 67: 1030-1037 [PMID: 17283135 DOI: 10.1158/0008-5472.CAN-06-2030]

148 Hermanna PC, Huber SL, Herrler T, Aicher A, Ellwatt JW, Gaba M, Bruns CJ, Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. *Cell Stem Cell* 2008; 3: 313-323 [PMID: 18371365 DOI: 10.1016/j.stem.2007.06.002]

149 Lenardon E, Hermann PC, Mueller MT, Huber S, Balic A, Miranda-Lorenzo I, Zagora S, Alcalas A, Rodriguez-Arabalaza I, Ramirez JC, Torres-Ruiz R, Garcia E, Hidalgo M, Cebrian DA, Heuchel R, Lohr M, Berger F, Bartenstein P, Aicher A, Heeschen C. Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. *Cell Stem Cell* 2011; 9: 433-446 [PMID: 22056140 DOI: 10.1016/j.stem.2011.10.001]

150 Lenardon E, Frias-Aldegueur J, Hermann PC, Heeschen C. Pancreatic stellate cells form a niche for cancer stem cells and promote their self-renewal and invasiveness. *Cell Cycle* 2012; 11: 1282-1290 [PMID: 22421149 DOI: 10.1089/cc.2011.0697]

151 Sainz B, Alcalas A, Garcia E, Sanchez-Ripoll Y, Azvedo MM, Cioffi M, Taturi M, Miranda-Lorenzo I, Hidalgo M, Gomez-Lopez G, Cahamero M, Eiran K, Kleefeld J, Garcia-Silva S, Sanapo P, Hermann PC, Heeschen C. Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment. *Gut* 2015; 64: 1921-1935 [PMID: 25841238 DOI: 10.1136/gutjnl-2014-308935]

152 Wahab ZA, Metzgar RS. Human cytotoxic lymphocytes reactive with pancreatic adenocarcinoma cells. *Pancreas* 1991; 6: 307-317 [PMID: 1862066 DOI: 10.1097/00006676-199105000-00008]

153 Yoshikawa K, Mitsuenga S, Kinoshita T, Komichi M, Takahashi
Gotohda N, Kato Y, Aizawa M, Ochiai A. Impact of tumor-associated macrophages on invasive ductal carcinoma of the pancreas head. Cancer Sci 2012; 103: 2012-2020 [PMID: 22934136 DOI: 10.1111/j.1349-7006.2012.02111.x]

164. Hao NB, Li MH, Fan YH, Cao YL, Zhige ZR, Yang SM. Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol 2012; 2012: 948098 [PMID: 22778768 DOI: 10.1155/2012/948098]

165. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007; 67: 9518-9527 [PMID: 17990862 DOI: 10.1158/0008-5472.CAN-07-0175]

166. van Kooten C. Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000; 67: 2-17 [PMID: 10467992]

167. Beatty GL, Chioere EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, Torneberg DA, O’Dwyer PJ, Vonderheide RH. CD40 agonists alter tumor stroma and show efficacy against pancreatic cancer in mice and humans. Science 2011; 331: 1612-1616 [PMID: 21436454 DOI: 10.1126/science.1189590]

168. Beatty GL, Torneberg DA, Chioere EG, Saboury B, Brothers A, Alavi A, Troxel AB, Sun W, Teitelbaum UR, Vonderheide RH, O’Dwyer PJ. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res 2013; 19: 6286-6295 [PMID: 23983255 DOI: 10.1158/1078-0432.CCR-13-1320]

169. Esposito I, Menicagli M, Funel N, Bergmann F, Boggi U, Mosca F, Bivolacqua G, Campani D. Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J Clin Pathol 2004; 57: 630-636 [PMID: 15166270 DOI: 10.1136/jcp.2003.014498]

170. Ino Y, Yamazaki-Itoh R, Shimada K, Iwashi M, Kosuge T, Kanai Y, Hiraoka N. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer 2013; 108: 914-923 [PMID: 23385730 DOI: 10.1038/bjc.2013.32]

171. Kurahara H, Shinoh H, Mataki Y, Maemura K, Noma H, Kubo F, Sakoda M, Ueno S, Natsugoe S, Takao S. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res 2011; 167: e211-e219 [PMID: 19765725 DOI: 10.1016/j.jss.2009.05.026]

172. Gardian K, Janczewska S, Olszewski WL, Durlik M. Analysis of macrophage microenvironment role of macrophage infiltrates and growth factors expression. J Cancer Res 2012; 10: 285-291 [PMID: 22773933 DOI: 10.7150/jca.4537]

173. Schoppmann SF, Birner P, Stöckl J, Kalt R, Ullrich SE. Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer. Cancer Res 2013; 73: 3927-3937 [PMID: 23633481 DOI: 10.1158/0008-5472.CAN-12-4479]

174. Schönhuber N, Seidler B, Schuck K, Veltkamp C, Schachtler C, Zukowska M, Eser S, Feyerabend TB, Paul MC, Eser P, Klein S, Lowy AM, Banerjee R, Yang F, Lee CL, Moding EJ, Kirsch DG, Scheideler A, Alessi DR, Varela I, Bradley A, Kind A, Schneie AE, Rodelwald HR, Rad R, Schmidt RM, Schneider G, Sauer D. A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer. Nat Med 2014; 20: 1340-1347 [PMID: 25326799 DOI: 10.1038/nm.3646]

175. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebien JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169: 2756-2761 [PMID: 12193750 DOI: 10.4049/jimmunol.169.5.2756]

176. Liyanage UK, Goedegebuure PS, Moore TT, Viehl CT, Moo-Young TA, Larson JW, Frey DM, Ehlers JP, Eberlein TJ, Linehan DC. Increased prevalence of regulatory T cells (Treg) is induced by pancreatic adenocarcinoma. J Immunother 2006; 29: 416-424 [PMID: 16799337 DOI: 10.1007/s10385-005-4373-4]

177. Nummer D, Suri-Payer E, Schmitz-Winnenthal H, Bonertz A, Galindo L, Antolovich D, Koch M, Büchner M, Weitz J, Schirrmacher V, Schemmer P. Role of tumor endothelium in CD4+ CD25+ regulatory T cell infiltration of human pancreatic carcinoma. J Natl Cancer Inst 2007; 99: 1188-1199 [PMID: 17652277 DOI: 10.1093/jnci/djm064]

178. Ence-Obong A, Clear AJ, Watt J, Wang J, Fatah R, Riches JC, Marshall JF, Chin-Aeong J, Chelala C, Gribben JG, Ramsay AG, Kocher HM. Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Gastroenterology 2013; 145: 1121-1132 [PMID: 23891972 DOI: 10.1053/j.gastro.2013.07.025]

179. Mace TA, Ameen Z, Collins A, Wojcik S, Mair M, Young GS,
Fuchs JR, Eibank TD, Frankel WL, Bekui-Saab T, Bloomston M, Lesinski GB. Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res 2013; 73: 3067-3018 [PMID: 23514705 DOI: 10.1158/0008-5472.CAN-12-4601]

Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015; 348: 56-61 [PMID: 25838373 DOI: 10.1126/science.aaa1872]

Royal RE, Levy C, Turner K, Mathur A, Hughes M, Niedergethmann M, Büchler P, Schmoll HJ, Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990; 348: 555-557 [PMID: 1701033 DOI: 10.1038/348555a0]

Hotz HG, Reber HA, Hotz B, Sanghavi PC, Yu T, Foitzik T, Bühr RJ, Hines OJ. Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth. J Gastrointest Surg 2001; 5: 131-138 [PMID: 11331474 DOI: 10.1016/S1091-255X(01)80024-X]

Jia L, Zhang MH, Yuan SZ, Huang WG. Antiangiogenic therapy for human pancreatic carcinoma xenografts in nude mice. World J Gastroenterol 2005; 11: 447-450 [PMID: 15637766 DOI: 10.3745/wjg.v11.i3.447]

Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, Taber DA, Parrish T, Dachman A, Jadus WM, Vokes EE. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005; 23: 8033-8040 [PMID: 16258101 DOI: 10.1200/JCO.2005.01.9661]

Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010; 28: 3617-3622 [PMID: 20606091 DOI: 10.1200/JCO.2010.28.1386]

Danish Pancreatic Cancer Database (DPCD). Lændekærende database for patienter med kraftigt i bugspytkirtlen 2014-2015 [In Danish]. Cited 2015.12.17. Available from: URL: http://www.dpcg.danmarksindforsikring.dk/danish
danish pancreatic cancer database (DCPD). Landsdækkende database for patienter med kraft i bugsytpytkirtlen 2014-2015 [In Danish]. Cited 2015.12.17. Available from: URL: http://www.dpcg.danmarksindforsikring.dk/danish

Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portnoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Dornfeld DD, Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413 [PMID: 9161656]

Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bacht J, Chellas-Azouz F, Pérès-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Dureux M, MULLERINO versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825 [PMID: 21306953 DOI: 10.1056/SJ/bjc.2014.00004-3]

Liss AS, Thayer SP. Therapeutic targeting of pancreatic stroma. In: Grippo PJ, Munshi HG, editors. Source: Pancreatic Cancer 2014: 223-224 [PMID: 24605023 DOI: 10.3748/wjg.v20.i9.2237]

Lutz E, Yeo CJ, Lilenko KD, Biedrzycki B, Kobrin B, Herman J, Sugar E, Piantadosi S, Cameron JL, Stolt S, Ommers B, Tartakovsky I, Choi M, Sharma R, Illie PB, Hruban RH, Abrams RA, Le D, Jaffe E, Laheru D. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy,
and immune activation. Ann Surg 2011; 253: 328-335 [PMID: 21217520 DOI: 10.1097/SLA.0b013e3181fd271c]

218 Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, Tartakovsky I, Nemunaitis J, Le D, Sugar E, Hege K, Jaffee E. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res 2008; 14: 1455-1463 [PMID: 18316569 DOI: 10.1158/1078-0432.CCR-07-0371]

219 Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, Zheng L, Diaz LA, Donehower RC, Jaffee EM, Laheru DA. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother 2013; 36: 382-389 [PMID: 23924790 DOI: 10.1097/CJI.0b013e31829fb7a2]

P- Reviewer: Kleeff J, Sperti C, Talukdar R  S- Editor: Ma YJ  L- Editor: A  E- Editor: Ma S
